PCI Pharma Services received a strategic investment co-led by Bain Capital and Kohlberg, with support from Mubadala, to accelerate its growth in CDMO, positioning the company for future success.

Jul 14, 2025•5 months ago

PhiladelphiaManufacturing

Investors

Partners GroupMubadala Investment CompanyKohlbergBain Capital

Description

PCI Pharma Services announced a strategic investment from Bain Capital and Kohlberg, with additional support from Mubadala. This investment aims to help PCI enhance its position in the contract development and manufacturing sector. The company will focus on both organic and inorganic growth initiatives. Financial terms of the transaction were not disclosed.

Company Information

Company

PCI Pharma Services

Location

Philadelphia, Pennsylvania, United States

About

PCI is your world leading CDMO, providing integrated end-to-end drug development, manufacturing, and packaging solutions to increase product speed to market and opportunities for commercial success. PCI brings the proven experience that comes with more than 90 successful product launches each year and over five decades in the delivery of CDMO services. With 30 sites across Australia, Canada, North America, the UK, and Europe and over 6000+ dedicated employees, together, delivering life changing therapies. Leading technology and continued investment enable us to deliver development to commercialization solutions throughout the product lifecycle, collaborating with our clients to improve the lives of patients globally.

Related People

2 contacts

Funding Insights

Based on industry data

VC-backed spending patterns